BACKGROUND: Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement in outcome. To the authors' knowledge, no validated predictive biomarkers for bevacizumab exist, although emerging data suggest that subsets of patients with APCA may benefit from treatment with bevacizumab. The authors evaluated baseline serum albumin (b-alb) as a predictive biomarker in a pooled analysis from 7 prospective clinical trials of gemcitabine-based therapy with or without bevacizumab. METHODS: Data were collected from individual databases from 7 prospective clinical trials. Patients were grouped by exposure to bevacizumab and by b-alb level (≥ 3.4 g/L or < 3.4 g/dL). Overall survival (OS), time to disease progression (TTP), overall response rate, and disease control rate (overall response rate plus stable disease lasting ≥ 16 weeks) were compared between groups. Univariate and multivariable analyses of prognostic factors were performed. RESULTS: A total of 264 patients were included. The median age was 59 years (range, 31 years-85 years) and all patients had stage IV disease per TNM staging. Normal b-alb was associated with significantly improved median OS (10.2 months vs 4.1 months; P = .0001), median TTP (6.2 months vs 3.7 months; P = 0.0488), and disease control rate (71% vs 46%; P = .007) for patients receiving bevacizumab, but not for those treated without bevacizumab. Multivariable analysis revealed a significant influence of normal b-alb on OS (P = .0008) and TTP (P = .033). CONCLUSIONS: Patients with APCA with normal b-alb derive benefit from treatment with bevacizumab. Future prospective investigations of bevacizumab in patients with APCA should consider selecting patients with normal b-alb to maximize potential benefit.
BACKGROUND: Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement in outcome. To the authors' knowledge, no validated predictive biomarkers for bevacizumab exist, although emerging data suggest that subsets of patients with APCA may benefit from treatment with bevacizumab. The authors evaluated baseline serum albumin (b-alb) as a predictive biomarker in a pooled analysis from 7 prospective clinical trials of gemcitabine-based therapy with or without bevacizumab. METHODS: Data were collected from individual databases from 7 prospective clinical trials. Patients were grouped by exposure to bevacizumab and by b-alb level (≥ 3.4 g/L or < 3.4 g/dL). Overall survival (OS), time to disease progression (TTP), overall response rate, and disease control rate (overall response rate plus stable disease lasting ≥ 16 weeks) were compared between groups. Univariate and multivariable analyses of prognostic factors were performed. RESULTS: A total of 264 patients were included. The median age was 59 years (range, 31 years-85 years) and all patients had stage IV disease per TNM staging. Normal b-alb was associated with significantly improved median OS (10.2 months vs 4.1 months; P = .0001), median TTP (6.2 months vs 3.7 months; P = 0.0488), and disease control rate (71% vs 46%; P = .007) for patients receiving bevacizumab, but not for those treated without bevacizumab. Multivariable analysis revealed a significant influence of normal b-alb on OS (P = .0008) and TTP (P = .033). CONCLUSIONS:Patients with APCA with normal b-alb derive benefit from treatment with bevacizumab. Future prospective investigations of bevacizumab in patients with APCA should consider selecting patients with normal b-alb to maximize potential benefit.
Authors: Andrew H Ko; Elizabeth Dito; Brian Schillinger; Alan P Venook; Emily K Bergsland; Margaret A Tempero Journal: J Clin Oncol Date: 2005-12-12 Impact factor: 44.544
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Christiane J Bruns; Marissa Shrader; Matthew T Harbison; Charles Portera; Carmen C Solorzano; K-W Jauch; Daniel J Hicklin; Robert Radinsky; Lee M Ellis Journal: Int J Cancer Date: 2002-11-10 Impact factor: 7.396
Authors: Andrew H Ko; Anne M Espinoza; Kimberly A Jones; Alan P Venook; Emily K Bergsland; Robin K Kelley; Elizabeth Dito; Anna Ong; Cherry S Hanover; Fergus V Coakley; Margaret A Tempero Journal: Am J Clin Oncol Date: 2012-10 Impact factor: 2.339
Authors: Hedy L Kindler; Tatsuya Ioka; Dirk J Richel; Jaafar Bennouna; Richard Létourneau; Takuji Okusaka; Akihiro Funakoshi; Junji Furuse; Young Suk Park; Shinichi Ohkawa; Gregory M Springett; Harpreet S Wasan; Peter C Trask; Paul Bycott; Alejandro D Ricart; Sinil Kim; Eric Van Cutsem Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Peter Büchler; Howard A Reber; Axel Ullrich; Mark Shiroiki; Mendel Roth; Markus W Büchler; Robert S Lavey; Helmut Friess; Oscar J Hines Journal: Surgery Date: 2003-11 Impact factor: 3.982
Authors: Zipeng Lu; Maximilian Weniger; Kuirong Jiang; Stefan Boeck; Kai Zhang; Alexander Bazhin; Yi Miao; Jens Werner; Jan G D'Haese Journal: Target Oncol Date: 2018-08 Impact factor: 4.493
Authors: Michael Haas; Christoph Kern; Stephan Kruger; Marlies Michl; Dominik P Modest; Clemens Giessen; Christoph Schulz; Jobst C von Einem; Steffen Ormanns; Rüdiger P Laubender; Stefan Holdenrieder; Volker Heinemann; Stefan Boeck Journal: Tumour Biol Date: 2014-12-04
Authors: Oliver Königsbrügge; Florian Posch; Julia Riedl; Eva-Maria Reitter; Christoph Zielinski; Ingrid Pabinger; Cihan Ay Journal: Oncologist Date: 2016-01-13
Authors: Andrew Hendifar; Arsen Osipov; Jasleen Khanuja; Nicholas Nissen; Jason Naziri; Wensha Yang; Quanlin Li; Richard Tuli Journal: PLoS One Date: 2016-03-25 Impact factor: 3.240